These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23122594)

  • 21. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
    Zhu LP; Xing J; Wang QX; Kou L; Li C; Hu B; Wu ZW; Wang JJ; Xu GX
    Eur J Pharmacol; 2009 Sep; 617(1-3):23-7. PubMed ID: 19615993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies of poly(ethylene glycol) modification of HM-3 polypeptides.
    Zhou K; Zheng X; Xu HM; Zhang J; Chen Y; Xi T; Feng T
    Bioconjug Chem; 2009 May; 20(5):932-6. PubMed ID: 19413309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Research of cloning, expression of human endostatin gene and its inhibition effects to the glioma in vivo].
    Zhang X; Wu J; Fei Z
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):783-7. PubMed ID: 11798965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble multimer of recombinant endostatin expressed in E. coli has anti-angiogenesis activity.
    Wei DM; Gao Y; Cao XR; Zhu NC; Liang JF; Xie WP; Zhen MY; Zhu MS
    Biochem Biophys Res Commun; 2006 Jul; 345(4):1398-404. PubMed ID: 16723120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI.
    Mulder WJ; van der Schaft DW; Hautvast PA; Strijkers GJ; Koning GA; Storm G; Mayo KH; Griffioen AW; Nicolay K
    FASEB J; 2007 Feb; 21(2):378-83. PubMed ID: 17202248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
    Folkman J
    Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
    Scappaticci FA; Smith R; Pathak A; Schloss D; Lum B; Cao Y; Johnson F; Engleman EG; Nolan GP
    Mol Ther; 2001 Feb; 3(2):186-96. PubMed ID: 11237675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR; Fu CC; Tsai ML; Chung WJ
    Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer].
    Zhou ZW; Wan DS; Wang GQ; Ren JQ; Lu ZH; Lin SX; Tang SX; Ye YL; Chen G
    Ai Zheng; 2006 Jul; 25(7):818-22. PubMed ID: 16831270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of the effect of rh-endostatin on intratumoral and myocardial micrangium in mice].
    Zhang CC; Li K; Wei XY; Chen C; Yuan J; Wang J
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):415-20. PubMed ID: 21875480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights.
    Chamani R; Asghari SM; Alizadeh AM; Eskandari S; Mansouri K; Khodarahmi R; Taghdir M; Heidari Z; Gorji A; Aliakbar A; Ranjbar B; Khajeh K
    Vascul Pharmacol; 2015 Sep; 72():73-82. PubMed ID: 26187352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: Glycol-split heparin-endostatin2 (GSHP-ES2).
    Sun F; Wang Z; Yang Z; Li Y; Cui H; Liu C; Gao D; Wang F; Tan H
    Carbohydr Polym; 2019 Mar; 207():79-90. PubMed ID: 30600066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin.
    Cheng W; Dahmani FZ; Zhang J; Xiong H; Wu Y; Yin L; Zhou J; Yao J
    Nanotechnology; 2017 Feb; 28(7):075102. PubMed ID: 28091396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fusion expression and identification of angiostatin and endostatin in E. coli BL21(DE3)].
    Mao X; Liu W; Fu S; Li R; Liang G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Oct; 23(5):1086-91. PubMed ID: 17121360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
    J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site.
    Park J; Hwang SR; Choi JU; Alam F; Byun Y
    Int J Pharm; 2018 Jan; 535(1-2):38-46. PubMed ID: 29097141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by the angiogenesis inhibitor endostatin].
    Zhang G; Wang Y; Zhang M; Wang Q; Luo Y; Han C; Lu Y; Rao Y
    Zhonghua Wai Ke Za Zhi; 2002 Jan; 40(1):59-61. PubMed ID: 11955383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.
    Aydin E; Kivilcim M; Peyman GA; Esfahani MR; Kazi AA; Sanders DR
    Cornea; 2008 May; 27(4):446-53. PubMed ID: 18434849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
    Yin R; Zheng H; Xi T; Xu HM
    Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.